Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Articles
BioCentury
|
Aug 31, 2017
Targets & Mechanisms
Necroptosis strikes again
...in ALS. Denali Therapeutics Inc. gained the rights to Yuan's RIPK1 program when it acquired
Incro Pharmaceuticals Corp.
...
Read More
BioCentury
|
Sep 12, 2016
Strategy
Dealing Denali
...the deals announced on Aug. 25 add three first-in-class pipeline programs from Genentech Inc. ,
Incro Pharmaceuticals Corp.
...
Read More
BioCentury
|
Sep 5, 2016
Company News
Incro Pharmaceuticals, Denali Therapeutics deal
...rights to the program from Harvard University (Cambridge, Mass.). Denali declined to disclose financial terms.
Incro Pharmaceuticals Corp.
...
Read More
BioCentury
|
Aug 25, 2016
Top Story
Denali unveils $130M funding, series of deals
...future trials in AD and ALS. The company gained the program through its acquisition of
Incro Pharmaceuticals
...
Read More
Items per page:
10
1 - 4 of 4
BioCentury
|
Aug 31, 2017
Targets & Mechanisms
Necroptosis strikes again
...in ALS. Denali Therapeutics Inc. gained the rights to Yuan's RIPK1 program when it acquired
Incro Pharmaceuticals Corp.
...
Read More
BioCentury
|
Sep 12, 2016
Strategy
Dealing Denali
...the deals announced on Aug. 25 add three first-in-class pipeline programs from Genentech Inc. ,
Incro Pharmaceuticals Corp.
...
Read More
BioCentury
|
Sep 5, 2016
Company News
Incro Pharmaceuticals, Denali Therapeutics deal
...rights to the program from Harvard University (Cambridge, Mass.). Denali declined to disclose financial terms.
Incro Pharmaceuticals Corp.
...
Read More
BioCentury
|
Aug 25, 2016
Top Story
Denali unveils $130M funding, series of deals
...future trials in AD and ALS. The company gained the program through its acquisition of
Incro Pharmaceuticals
...
Read More
Items per page:
10
1 - 4 of 4
Previous page
Next page